Argos Therapeutics Inc (NASDAQ:ARGS)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $2.12 and last traded at $0.13, with a volume of 17910200 shares trading hands. The stock had previously closed at $0.16.

The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of -1.46. The firm has a market cap of $199.48, a P/E ratio of -1.97 and a beta of 1.38.

Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent reporting period. 18.35% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/19/argos-therapeutics-args-sets-new-52-week-low-at-2-12.html.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.